Key result
Intensive SBP control shows no cognitive benefit over standard treatment in older hypertensive patients.
Why the study?
While intensive SBP control reduced cardiovascular events in the STEP trial, its effects on cognitive function remained to be analyzed.
Does intensive systolic blood pressure control improve cognitive function in older hypertensive patients?
RCT (n=6,501)
1:1
Yes
Does intensive systolic blood pressure control improve cognitive function in older hypertensive patients?
Effect estimate: Mean difference -0.031 (95% CI -0.058, -0.005)
Absolute Event Rate: -0.001% vs 0.03%
p-value: p=0.052
Intensive systolic blood pressure control (110-130 mmHg) did not significantly change cognitive function test scores compared to standard treatment (130-150 mmHg) over a median of 3.34 years.
Intensive SBP control does not improve cognition in older hypertensives; challenges prior hypotheses and leaves optimal targets for longer trials unresolved.
Background The STEP (Strategy of Blood Pressure Intervention in the older Hypertensive Patients) trial showed that intensive systolic blood pressure (SBP) control resulted in a lower incidence of cardiovascular events than standard treatment. This study analyzed the effects of intensive SBP lowering on cognitive function. Methods STEP was a multicenter, randomized controlled trial of hypertensive patients aged 60–80 years. Participants were randomly assigned (1:1) to SBP goals of 110–130 mmHg (intensive treatment) or 130–150 mmHg (standard treatment). Each individual was asked to complete a cognitive function test (Mini-Mental State Examination; MMSE) at baseline and during follow-up. The primary outcome for this study was the annual change in MMSE score. Subjects with a score less than education-specific cutoff point were categorized as cognitive decline. Results The analysis enrolled 6,501 participants (3,270 participants in the intensive-treatment and 3,231 participants in the standard-treatment groups). Median follow-up was 3.34 years. There was a minor change in MMSE score, with an annual change of −0.001 [95% confidence interval [CI] −0.020, 0.018] and 0.030 (95% CI 0.011, 0.049) in the intensive- and standard-treatment groups, respectively ( p = 0.052). Cognitive decline occurred in 46/3,270 patients (1.4%) in the intensive-treatment group and 42/3,231 (1.3%) in the standard-treatment group (hazard ratio 0.005, 95% CI 0.654, 1.543, p = 0.983). Conclusions Compared with standard treatment, intensive SBP treatment did not result in a significant change in cognitive function test score. The impact of intensive blood pressure lowering was not evident using this global cognitive function test. Trial registration ClinicalTrials.gov . Unique identifier: NCT03015311.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2023) conducted an RCT in Hypertension (n=6,501). Intensive systolic blood pressure control vs. Standard treatment (target 130-150 mmHg) was evaluated on Annual change in MMSE score (Mean difference -0.031, 95% CI -0.058, -0.005, p=0.052). Intensive systolic blood pressure control did not result in a significant change in cognitive function test scores compared to standard treatment in older hypertensive patients (p=0.052).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: